(Total Views: 465)
Posted On: 03/25/2017 6:24:11 PM
Post# of 30066
.jpg)
In July 2014, we went to the #C4CT at the United Nations building with NFL players, politicians, and key opinion leaders on the back of "positive" top line data for our brand new Alzheimer's diagnostic. And here our stock price peaked.
That fall, even as we completed trials for Lympro, started CLIA, and announced "positive" data, we were parlaying a failing diagnostic into financing for the acquisition of a new asset from Lonza/RGIN, ESS which we announced in November 2014 as the 50 day moving average crossed below the 200 day moving average.
Most of you know this, in painful detail, though it seems so hard to remember now in 2017. Now, the 50 day moving average looks to break the 200 day moving average for the first time in two and a half years later. Two and a half years of slow, then precipitous decline in our accounts, with hope always on the horizon.
Let us not forget the mountain of positive,sometimes exuberant, but conclusive MANF research published inbetween and ongoing, including on the method of delivery and the progress in gene therapy. Let us not forget the support legs we developed that can still have us standing under a blue sky: eltoprazine, ESS, and AMBS diagnostics/Avant. All we need is someone to clean up our finances and apply a network to rapidly parter these promising assets.
That fall, even as we completed trials for Lympro, started CLIA, and announced "positive" data, we were parlaying a failing diagnostic into financing for the acquisition of a new asset from Lonza/RGIN, ESS which we announced in November 2014 as the 50 day moving average crossed below the 200 day moving average.
Most of you know this, in painful detail, though it seems so hard to remember now in 2017. Now, the 50 day moving average looks to break the 200 day moving average for the first time in two and a half years later. Two and a half years of slow, then precipitous decline in our accounts, with hope always on the horizon.
Let us not forget the mountain of positive,sometimes exuberant, but conclusive MANF research published inbetween and ongoing, including on the method of delivery and the progress in gene therapy. Let us not forget the support legs we developed that can still have us standing under a blue sky: eltoprazine, ESS, and AMBS diagnostics/Avant. All we need is someone to clean up our finances and apply a network to rapidly parter these promising assets.
(10)
(0)
